Article information
Full text is only aviable in PDF
References
[1]
A.A. Hagege, E. Caudron, T. Damy, et al.
Screening patients with hypertrophic cardiomyopathy for fabry disease using a filter-paper test: the focus study.
Heart, 97 (2011), pp. 131-136
[2]
I. Olivotto, B.J. Maron, E. Appelbaum, et al.
Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy.
Am J Cardiol, 106 (2010), pp. 261-267
[3]
R. O’Hanlon, A. Grasso, M. Roughton, et al.
Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy.
J Am Coll Cardiol, 56 (2010), pp. 867-874
[4]
O. Bruder, A. Wagner, C.J. Jensen, et al.
Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.
J Am Coll Cardiol, 56 (2010), pp. 875-887
[5]
A.S. Flett, M.P. Hayward, M.T. Ashworth, et al.
Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans.
Circulation, 122 (2010), pp. 138-144
[6]
C.Y. Ho, B. Lopez, O.R. Coelho-Filho, et al.
Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy.
N Engl J Med, 363 (2010), pp. 552-563
[7]
Ingles J, McGaughran J, Scuffham PA, et al. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart. 2011 Nov 29. [Epub ahead of print]. PMID: 22128210. doi:10.1136/heartjnl-2011-300368.
[8]
S. Wordsworth, J. Leal, E. Blair, et al.
DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.
Eur Heart J, 31 (2010), pp. 926-935
[9]
S. Agarwal, E.M. Tuzcu, M.Y. Desai, et al.
Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy.
J Am Coll Cardiol, 55 (2010), pp. 823-834
[10]
F.J. Ten Cate, O.I. Soliman, M. Michels, et al.
Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution.
Circ Heart Fail, 3 (2010), pp. 362-369
[11]
R.A. Nishimura, S.R. Ommen.
Septal reduction therapy for obstruc-tive hypertrophic cardiomyopathy and sudden death: what statistics cannot tell you.
Circ Cardiovasc Interv, 3 (2010), pp. 91-93
[12]
R.A. Leonardi, E.P. Kransdorf, D.L. Simel, et al.
Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment.
Circ Cardiovasc Interv, 3 (2010), pp. 97-104
[13]
T. Lawrenz, B. Borchert, C. Leuner, et al.
Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months’ follow-up in 19 patients.
J Am Coll Cardiol, 57 (2011), pp. 572-576
[14]
E. Galve, A. Sambola, G. Saldana, et al.
Late benefits of dualchamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study.
Heart, 96 (2010), pp. 352-356
[15]
S.A. Mohiddin, S.P. Page.
Long-term benefits of pacing in obstructive hypertrophic cardiomyopathy.
Heart, 96 (2010), pp. 328-330
[16]
J.M. Bos, B.J. Maron, M.J. Ackerman, et al.
Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy.
Am J Cardiol, 106 (2010), pp. 1481-1486
[17]
I. Christiaans, K. van Engelen, I.M. van Langen, et al.
Risk stratification for sudden cardiac death in hypertrophic car-diomyopathy: systematic review of clinical risk markers.
Europace, 12 (2010), pp. 313-321
[18]
O’Mahony C, Lambiase PD, Quarta G, et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic car-diomyopathy. Heart. Published Online First: 13 July 2011. doi:10.1136/hrt.2010.217182.
[19]
J.P. Kaski, P. Syrris, M.T. Esteban, et al.
Prevalence of sarcom-ere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy.
Circ Cardiovas Genet, 2 (2009), pp. 436-441
[20]
Moak JP, Leifer ES, Tripodi D, et al. Long-term follow-up of children and adolescents diagnosed with hypertrophic cardiomyopathy: risk factors for adverse arrhythmic events. Pediatr Cardiol. Published Online First: 13 April 2011. PMID: 21487794.
[21]
D. Gao, N. Ning, X. Niu, et al.
Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
Heart, 97 (2011), pp. 278-286
[22]
K. Abozguia, P. Elliott, W. McKenna, et al.
Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.
Circulation, 122 (2010), pp. 1562-1569
[23]
D. Corrado, C. Basso, K. Pilichou, et al.
Molecular biology and clinical management of arrhythmogenic right ventricular cardiomyopathy/dysplasia.
Heart, 97 (2011), pp. 530-539
[24]
F.I. Marcus, W.J. McKenna, D. Sherrill, et al.
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria.
Eur Heart J, 31 (2010), pp. 806-814
[25]
V. Fressart, G. Duthoit, E. Donal, et al.
Desmosomal gene analysis in arrhythmogenic right ventricular dysplasia/cardiomyopathy: spectrum of mutations and clinical impact in practice.
Europace, 12 (2010), pp. 861-868
[26]
Otten E, Asimaki A, Maass A, et al. Desmin mutations as a cause of right ventricular heart failure affect the intercalated disks. Heart Rhythm. 2010; 7:1058-1064, the official journal of the Heart Rhythm Society.
[27]
B. Klauke, S. Kossmann, A. Gaertner, et al.
De novo desmin-mutation n116s is associated with arrhythmogenic right ventricular cardiomyopathy.
Hum Mol Genet, 19 (2010), pp. 4595-4607
[28]
M. Taylor, S. Graw, G. Sinagra, et al.
Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syn-dromes.
Circulation, 124 (2011), pp. 876-885
[29]
J.D. Kapplinger, A.P. Landstrom, B.A. Salisbury, et al.
Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise.
J Am Coll Cardiol, 57 (2011), pp. 2317-2327
[30]
M.G. Cox, P.A. van der Zwaag, C. van der Werf, et al.
Arrhythmo-genic right ventricular dysplasia/cardiomyopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dys-plasia/cardiomyopathy genotype-phenotype follow-up study.
Circulation, 123 (2011), pp. 2690-2700
[31]
G. Quarta, A. Muir, A. Pantazis, et al.
Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria.
Circulation, 123 (2011), pp. 2701-2709
[32]
N. Protonotarios, A. Anastasakis, L. Antoniades, et al.
Arrhythmo-genic right ventricular cardiomyopathy/dysplasia on the basis of the revised diagnostic criteria in affected families with desmo-somal mutations.
Eur Heart J, 32 (2011), pp. 1097-1104
[33]
A. La Gerche, C. Robberecht, C. Kuiperi, et al.
Lower than expected desmosomal gene mutation prevalence in endurance athletes with complex ventricular arrhythmias of right ventric-ular origin.
Heart, 96 (2010), pp. 1268-1274
[34]
G. Quarta, D. Ward, M.T. Tome Esteban, et al.
Dynamic electro-cardiographic changes in patients with arrhythmogenic right ventricular cardiomyopathy.
Heart, 96 (2010), pp. 516-522
[35]
D. Corrado, H. Calkins, M.S. Link, et al.
Prophylactic implantable defibrillator in patients with arrhythmogenic right ven-tricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia.
Circulation, 122 (2010), pp. 1144-1152
[36]
S.A. Wiltshire, G.A. Leiva-Torres, S.M. Vidal.
Quantitative trait locus analysis, pathway analysis, and consomic mapping show genetic variants of tnni3k, fpgt, or h28 control susceptibility to viral myocarditis.
J Immunol, 186 (2011), pp. 6398-6405
[37]
C. Gorbea, K.A. Makar, M. Pauschinger, et al.
A role for toll-like receptor 3 variants in host susceptibility to enterovi-ral myocarditis and dilated cardiomyopathy.
J Biol Chem, 285 (2010), pp. 23208-23223
[38]
B.D. Horne, K.D. Rasmusson, R. Alharethi, et al.
Genome-wide sig-nificance and replication of the chromosome 12p11.22 locus near the pthlh gene for peripartum cardiomyopathy.
Circ Car-diovasc Genet, 4 (2011), pp. 359-366
[39]
K.Y. van Spaendonck-Zwarts, J.P. van Tintelen, D.J. van Veldhuisen, et al.
Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy.
Circulation, 121 (2010), pp. 2169-2175
[40]
Y.M. Hoedemaekers, K. Caliskan, M. Michels, et al.
The importance of genetic counseling, DNA diagnostics, and cardiologic fam-ily screening in left ventricular noncompaction cardiomyopathy.
Circ Cardiovasc Genet, 3 (2010), pp. 232-239
[41]
P. Elliott, C. O’Mahony, P. Syrris, et al.
Prevalence of desmosomal protein gene mutations in patients with dilated cardiomyopa-thy.
Circ Cardiovasc Genet, 3 (2010), pp. 314-322
[42]
P. Garcia-Pavia, P. Syrris, C. Salas, et al.
Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinicopathological study.
Heart, 97 (2011), pp. 1744-1752
[43]
J. Cowan, D. Li, J. Gonzalez-Quintana, et al.
Morphological anal-ysis of 13 lmna variants identified in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy.
Circ Cardiovasc Genet, 3 (2010), pp. 6-14
[44]
C. Caleshu, S. Day, H.L. Rehm, et al.
Use and interpre-tation of genetic tests in cardiovascular genetics.
Heart, 96 (2010), pp. 1669-1675
[45]
G. Millat, P. Bouvagnet, P. Chevalier, et al.
Clinical and mutational spectrum in a cohort of 105 unrelated patients with dilated cardiomyopathy.
Eur J Med Genet, 54 (2011), pp. e570-e575
[46]
D.V. Moller, P.S. Andersen, P. Hedley, et al.
The role of sarcomere gene mutations in patients with idiopathic dilated cardiomy-opathy.
Eur J Hum Genet, 17 (2009), pp. 1241-1249
[47]
S. Probst, E. Oechslin, P. Schuler, et al.
Sarcomere gene muta-tions in isolated left ventricular noncompaction cardiomyopathy do not predict clinical phenotype.
Circ Cardiovasc Genet, 4 (2011), pp. 367-374
[48]
E. Rampersaud, J.D. Siegfried, N. Norton, et al.
Rare variant mutations identified in pediatric patients with dilated car-diomyopathy.
Prog Pediatr Cardiol, 31 (2011), pp. 39-47
[49]
C. Caleshu, R. Sakhuja, R.L. Nussbaum, et al.
Furthering the link between the sarcomere and primary cardiomyopathies: restrictive cardiomyopathy associated with multiple mutations in genes previously associated with hypertrophic or dilated car-diomyopathy.
Am J Med Genet A, 155A (2011), pp. 2229-2235
[50]
J.P. Kaski, P. Syrris, M. Burch, et al.
Idiopathic restrictive cardiomy-opathy in children is caused by mutations in cardiac sarcomere protein genes.
Heart, 94 (2008), pp. 1478-1484
[51]
F. Girolami, C.Y. Ho, C. Semsarian, et al.
Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations.
J Am Coll Cardiol, 55 (2010), pp. 1444-1453
[52]
R.E. Hershberger, N. Norton, A. Morales, et al.
Coding sequence rare variants identified in mybpc3, myh6, tpm1, tnnc1, and tnni3 from 312 patients with familial or idiopathic dilated car-diomyopathy.
Circ Cardiovasc Genet, 3 (2010), pp. 155-161
[53]
E. Rampersaud, D.D. Kinnamon, K. Hamilton, et al.
Common susceptibility variants examined for association with dilated cardiomyopathy.
Ann Hum Genet, 74 (2010), pp. 110-116
[54]
T.Z. Armel, L.A. Leinwand.
Mutations at the same amino acid in myosin that cause either skeletal or cardiac myopa-thy have distinct molecular phenotypes.
J Mol Cell Cardiol, 48 (2010), pp. 1007-1013
[55]
M.G. Friedrich, U. Sechtem, J. Schulz-Menger, et al.
Cardiovascular magnetic resonance in myocarditis: a jacc white paper.
J Am Coll Cardiol, 53 (2009), pp. 1475-1487
[56]
P.A. Monney, N. Sekhri, T. Burchell, et al.
Acute myocarditis presenting as acute coronary syndrome: role of early cardiac magnetic resonance in its diagnosis.
Heart, 97 (2010), pp. 1312-1318
[57]
G. Leurent, B. Langella, C. Fougerou, et al.
Diagnostic contributions of cardiac magnetic resonance imaging in patients presenting with elevated troponin, acute chest pain syndrome and unobstructed coronary arteries.
Arch Cardiovasc Dis, 104 (2011), pp. 161-170
[58]
R.G. Assomull, S.K. Prasad, J. Lyne, et al.
Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy.
J Am Coll Cardiol, 48 (2006), pp. 1977-1985
[59]
S. Lehrke, D. Lossnitzer, M. Schob, et al.
Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy.
Heart, 97 (2011), pp. 727-732
[60]
Malaty AN, Shah DJ, Abdelkarim AR, et al. Relation of replacement fibrosis to left ventricular diastolic function in patients with dilated cardiomyopathy. J Am Soc Echocardiogr. 2011; 24:333-338, official publication of the American Society of Echocardiography.
[61]
Holmstrom M, Kivisto S, Helio T, et al. Late gadolinium enhanced cardiovascular magnetic resonance of lamin a/c gene mutation related dilated cardiomyopathy. J Cardiovasc Magn Reson. 2011; 13:30, official journal of the Society for Cardiovascular Magnetic Resonance.
[62]
G. Nucifora, G.D. Aquaro, A. Pingitore, et al.
Myocardial fibrosis in isolated left ventricular non-compaction and its relation to disease severity.
Eur J Heart Fail, 13 (2011), pp. 170-176
[63]
P. Alter, H. Rupp, P. Adams, et al.
Occurrence of late gadolinium enhancement is associated with increased left ventricular wall stress and mass in patients with non-ischaemic dilated cardiomyopathy.
Eur J Heart Fail, 13 (2011), pp. 937-944
[64]
K.C. Wu, R.G. Weiss, D.R. Thiemann, et al.
Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy.
J Am Coll Cardiol, 51 (2008), pp. 2414-2421
[65]
K. Tigen, T. Karaahmet, C. Kirma, et al.
Diffuse late gadolinium enhancement by cardiovascular magnetic resonance predicts significant intraventricular systolic dyssynchrony in patients with non-ischemic dilated cardiomyopathy.
J Am Soc Echocardiogr, 23 (2010), pp. 416-422
[66]
F. Escher, D. Westermann, R. Gaub, et al.
Development of diastolic heart failure in a 6-year follow-up study in patients after acute myocarditis.
Heart, 97 (2011), pp. 709-714
[67]
Dickstein K, Vardas PE, Auricchio A, et al. 2010 focused update of esc guidelines on device therapy in heart failure: an update of the 2008 esc guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 esc guide-lines for cardiac and resynchronization therapy. Developed with the special contribution of the heart failure association and the european heart rhythm association. Eur Heart J. 2010; 31: 2677–87.
[68]
D.M. McNamara, R.C. Starling, L.T. Cooper, et al.
Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy results of the IMAC (intervention in myocarditis and acute cardiomyopathy)-2 study.
J Am Coll Cardiol, 58 (2011), pp. 1112-1118
[69]
A. Verma, Z. Wulffhart, D. Lakkireddy, et al.
Incidence of left ventricular function improvement after primary prevention icd implantation for non-ischaemic dilated cardiomyopathy: a multicentre experience.
Heart, 96 (2010), pp. 510-515
[70]
C. Meune, J.H. Van Berlo, F. Anselme, et al.
Primary prevention of sudden death in patients with lamin a/c gene mutations.
N Engl J Med, 354 (2006), pp. 209-210
[71]
E.M. McNally, D. Sparano.
Mechanisms and management of the heart in myotonic dystrophy.
Heart, 97 (2011), pp. 1094-1100
[72]
B. Lallemand, N. Clementy, A.B. Brunet, et al.
The evolution of infrahissian conduction time in myotonic dystrophy patients: clinical implications.
Heart, 98 (2012), pp. 291-296
[73]
R.J. van Bommel, N.A. Marsan, V. Delgado, et al.
Cardiac resyn-chronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high oper-ative risk.
Circulation, 124 (2011), pp. 912-919
[74]
A. Rossi, F.L. Dini, P. Faggiano, et al.
Independent prognostic value of functional mitral regurgitation in patients with heart fail-ure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy.
Heart, 97 (2011), pp. 1675-1680
[75]
M. Bertini, M. Ziacchi, M. Biffi, et al.
Effects of cardiac resyn-chronisation therapy on dilated cardiomyopathy with isolated ventricular non-compaction.
Heart, 97 (2011), pp. 295-300
[76]
E. Agricola, M. Oppizzi, M. Galderisi, et al.
Role of regional mechanical dyssynchrony as a determinant of functional mitral regurgitation in patients with left ventricular systolic dysfunc-tion.
Heart, 92 (2006), pp. 1390-1395
[77]
Donal E, De Place C, Kervio G, et al. Mitral regurgitation in dilated cardiomyopathy: value of both regional left ven-tricular contractility and dyssynchrony. Eur J Echocardiogr. 2009; 10:133-138, the journal of the Working Gro**up on Echocar-diography of the European Society of Cardiology.
[78]
C. Chiu, R.D. Bagnall, J. Ingles, et al.
Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis.
J Am Coll Cardiol, 55 (2010), pp. 1127-1135
[79]
K.M. Brauch, M.L. Karst, K.J. Herron, et al.
Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopa-thy.
J Am Coll Cardiol, 54 (2009), pp. 930-941
[80]
A. Morales, T. Painter, R. Li, et al.
Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy.
Circulation, 121 (2010), pp. 2176-2182
[81]
T. Arimura, J.M. Bos, A. Sato, et al.
Cardiac ankyrin repeat protein gene (ankrd1) mutations in hypertrophic cardiomyopathy.
J Am Coll Cardiol, 54 (2009), pp. 334-342
[82]
M. Moulik, M. Vatta, S.H. Witt, et al.
Ankrd1, the gene encoding car-diac ankyrin repeat protein, is a novel dilated cardiomyopathy gene.
J Am Coll Cardiol, 54 (2009), pp. 325-333
[83]
E. Villard, C. Perret, F. Gary, et al.
A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy.
Eur Heart J, 32 (2011), pp. 1065-1076
[84]
N. Norton, D. Li, M.J. Rieder, et al.
Genome-wide studies of copy number variation and exome sequencing identify rare variants in bag3 as a cause of dilated cardiomyopathy.
Am J Hum Genet, 88 (2011), pp. 273-282
[85]
G.G. Neely, K. Kuba, A. Cammarato, et al.
A global in vivo drosophila rnai screen identifies not3 as a conserved regulator of heart function.
Cell, 141 (2010), pp. 142-153
[86]
K.V. Voelkerding, S. Dames, J.D. Durtschi.
Next generation sequencing for clinical diagnostics-principles and application to targeted resequencing for hypertrophic cardiomyopathy: a paper from the 2009 william beaumont hospital symposium on molecular pathology.
J Mol Diagn, 12 (2010), pp. 539-551
[87]
J.S. Ware, A.M. Roberts, S.A. Cook.
Next generation sequencing for clinical diagnostics and personalised medicine: implications for the next generation cardiologist.
Heart, 98 (2012), pp. 276-281
[88]
S. Dames, J. Durtschi, K. Geiersbach, et al.
Comparison of the illu-mina genome analyzer and roche 454 gs flx for resequencing of hypertrophic cardiomyopathy-associated genes.
J Biomol Tech, 21 (2010), pp. 73-80
[89]
B. Meder, J. Haas, A. Keller, et al.
Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomy-opathies.
Circ Cardiovasc Genet, 4 (2011), pp. 110-122
[90]
S. Gowrisankar, J.P. Lerner-Ellis, S. Cox, et al.
Evaluation of second-generation sequencing of 19 dilated cardiomyopa-thy genes for clinical applications.
J Mol Diagnost, 12 (2010), pp. 818-827
Secondary publication: This article was published in its entirety, with the consent of the authors and editors, in Heart. 2011;97:1914–9.
Copyright © 2012. Sociedade Portuguesa de Cardiologia
